vigabatrin การใช้

• Vigabatrin would elevate GVG ( gamma-vinyl gamma-aminobutyric acid ).
• -Tiagabine, topiramate and a drug sold overseas as Vigabatrin; seizures.
• The rate is comparable to that of felbamate, vigabatrin, and topiramate.
• Vigabatrin helps lower GHB levels through GABA transaminase inhibition.
• The company told Dewey it would not release vigabatrin to the federal government for trials.
• Vigabatrin controls another brain chemical, GVG, which flips the " off " switch for dopamine.
• Vigabatrin, he reasoned, would elevate GVG ( short for gamma-vinyl gamma-aminobutyric acid ).
• Called gamma-vinyl GABA, GVG or vigabatrin, it is used to treat epilepsy in other countries.
• After zonisamide, other new anticonvulsants came onto the market : felbamate, gabapentin, lamotrigine, and vigabatrin.
• Where Vigabatrin is prescribed for epilepsy, its users, mainly children, take 2 to 4 grams a day.
• One day in 1991, Dewey was struck by the thought that vigabatrin might be useful in treating drug addiction.
• Dewey asked the company that made vigabatrin, then Hoechst AG, for a supply of the drug for testing.
• In experiments conducted in his laboratory, rats trained to take cocaine rejected the drug when they were given vigabatrin.
• Some patients develop psychosis during the course of vigabatrin therapy, which is more common in adults than in children.
• Vigabatrin is known for being effective, especially in children with tuberous sclerosis, with few and benign side effects.
• Given vigabatrin, animals that had been trained to take cocaine ignored the bar they used to tap for the drug.
• Felbamate and vigabatrin are newer AEDs, but can have serious adverse effects so they are not considered first-line treatments.
• When they entered a chamber where they had taken cocaine before, rats given vigabatrin acted as though they had never been there.
• Vigabatrin is also indicated for monotherapy use in secondarily generalized tonic-clonic seizures, partial seizures, and in infantile spasms due to West syndrome.
• On August 21, 2009, Lundbeck announced that the U . S . Food and Drug Administration had granted two New Drug Application approvals for vigabatrin.